Replies to post #234184 on Innovation Pharmaceuticals Inc (IPIX)

[DaubersUP]

Okay fine. Maybe I was a little over the top. But I feel otc investors are mostly short term and could care less about the phase2a strict criteria.

[georgejjl]

I agree 100%

Leo Ehrlich, Chief Executive Officer of Cellceutix, commented: “We had always wanted to explore Prurisol’s clinical merit, as it had excellent results in laboratory studies. We put it to the test under some of the most demanding conditions, with respect to the IGA versus PASI scoring systems; short treatment duration; low dosing levels; enrollment that included patients who were previously treated with biologics; and evaluation in mild to moderate psoriasis patients, where it can be more difficult to achieve a meaningful therapeutic effect. To see such a strong response among patients, achieving clear to almost clear skin without serious side effects—the downside of biologics—in such a short period of time, is exceptional.

http://www.ipharminc.com/press-release/2016/11/12/cellceutix-phase-2-trial-of-prurisol-for-mild-to-moderate-psoriasis-meets-primary-endpoint

Leo is alluding to a level of efficacy, minus AEs, that is unheard of in psoriatic drug development. I think we shareholders are in for a real treat.

Good luck and GOD bless,

George